Kindstar Globalgene Technology, Inc. (Kindstar Globalgene) disclosed that it repurchased 55,000 ordinary shares on 30 June 2026 via on-exchange transactions under its existing buyback mandate.

The shares were bought at prices ranging between HKD 0.94 and HKD 0.99, resulting in an aggregate consideration of HKD 0.05 million and an average cost of HKD 0.94 per share. All repurchased shares have been retained as treasury stock.

Following the transaction, the number of issued shares (excluding treasury shares) fell by 0.00532% to 1.03 billion, while treasury shares increased to 7.45 million. The company’s total issued share count remains unchanged at 1.04 billion because the repurchased shares have not been cancelled.

The buyback forms part of a mandate approved on 05 June 2026 that authorises the repurchase of up to 103.43 million shares. To date, Kindstar Globalgene has repurchased 384,000 shares under this mandate, representing 0.04% of the shares outstanding on the approval date, leaving capacity to repurchase a further 103.04 million shares.

Under Hong Kong Stock Exchange rules, the company is subject to a moratorium on issuing new shares or disposing of treasury shares until 30 July 2026.